Short-term effects of SGLT2 inhibitors on myocardial extracellular volume, left ventricular function and inflammation in patients with HFpEF and diabetes mellitus
Guideline-directed medication therapy use among patients with HFrEF receiving vericiguat: comparing findings from a real-world study to clinical trials
Impact of comprehensive heart failure management initiated during hospitalization on clinical outcomes in patients with decompensated heart failure with reduced ejection fraction
Speaker:
Associate Professor R. Christodorescu (Timisoara, RO)
Residual risk of hospitalization & all-cause mortality among patients with heart failure with reduced ejection fraction without worsening heart failure who received guideline-directed medical therapy
Cardiac cGMP augmentation and hemodynamic improvement in heart failure with reduced ejection fraction: evidence from sacubitril/valsartan and vericiguat treatment